Details for New Drug Application (NDA): 021785
✉ Email this page to a colleague
The generic ingredient in INVIRASE is saquinavir mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the saquinavir mesylate profile page.
Summary for 021785
Tradename: | INVIRASE |
Applicant: | Hoffmann-la Roche |
Ingredient: | saquinavir mesylate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 021785
Mechanism of Action | Cytochrome P450 3A Inhibitors HIV Protease Inhibitors |
Suppliers and Packaging for NDA: 021785
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785 | NDA | Genentech, Inc. | 0004-0244 | 0004-0244-51 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0004-0244-51) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
Approval Date: | Dec 17, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021785
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription